2022.09.20
Angitia Biopharmaceuticals Announces Positive Topline Results from AGA111 Phase 1/2 Trial for Spinal Fusion
Guangzhou, Guangdong, China, and Woodland Hills, California, USA: Angitia Biopharmaceuticals (Angitia) today announced the successful conclusion and positive top-line results of a phase 1/2 study entitled ‘A randomized, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of a single intervertebral administration of AGA111 in patients with degenerative disc disease undergoing interbody fusion’. The results from this trial demonstrated an excellent safety profile and preliminary efficacy in increasing fusion rate and improving clinical outcome.
2022.06.29
Angitia Biopharmaceuticals Announces First Subject Dosed in Phase I Clinical Trial of AGA2118
Angitia Biopharmaceuticals Announces First Subject Dosed in Phase I Clinical Trial of AGA2118
2022.06.15
FDA Grants Rare Pediatric Disease Designation (RPDD) to Angitia's AGA2115 for the Treatment of Osteogenesis Imperfecta
Angitia is delighted to announce that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to Angitia's investigational therapy AGA2115 for the treatment of Osteogenesis Imperfecta (OI), a life-threatening genetic skeletal disease, under Section 529(a)(3) of the Federal Food, Drug, and Cometic Act (the FD&C Act) (21 U.S.C. 360ff(a)(3)).
